Logo
Subscribe Now

Biosimilars

Boehringer Ingelheim's Cyltezo (biosimilar- adalimumab) Receives the US FDA's sBLA Approval as the 1st Interchangeable Biosimilar for Multiple Chronic Inflammatory Diseases

Boehringer Ingelheim's Cyltezo (biosimilar- adalimumab) Receives the US FDA's sBLA Approval as the 1st Interchangeable Biosimilar for Multiple Chronic Inflammatory Diseas...

Shots: The approval is ba...

Bio-Thera Expands its Partnership with Pharmapark to Commercialize BAT2206 (biosimilar- ustekinumab in Russia and other CIS Countries

Bio-Thera Expands its Partnership with Pharmapark to Commercialize BAT2206 (biosimilar- ustekinumab in Russia and other CIS Countries

Shots: Pharmapark to get...

Gan & Lee Completes P-III Studies of GL-GLA for Patients with T1D & T2D

Gan & Lee Completes P-III Studies of GL-GLA for Patients with T1D & T2D

Shots: The company comple...

Polpharma Biologics Reports the US FDA's Acceptance of BQ201's (biosimilar- ranibizumab) BLA for Review to Treat Wet Age-Related Macular Degeneration

Polpharma Biologics Reports the US FDA's Acceptance of BQ201's (biosimilar- ranibizumab) BLA for Review to Treat Wet Age-Related Macular Degeneration

Shots: The US FDA has iss...

Coherus Report Results of CHS-201 (biosimilar- ranibizumab) in COLUMBUS-AMD Clinical Trial for the Treatment of nAMD

Coherus Report Results of CHS-201 (biosimilar- ranibizumab) in COLUMBUS-AMD Clinical Trial for the Treatment of nAMD

Shots: The COLUMBUS-AMD t...

Apobiologix's Bambevi (biosimilar- bevacizumab) Receives Health Canada Approval for Multiple Cancer Indications

Apobiologix's Bambevi (biosimilar- bevacizumab) Receives Health Canada Approval for Multiple Cancer Indications

Shots: Apobiologix expand...

Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2021 PharmaShots - All Rights Reserved.